Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
April 2017 Volume 16 Number 4 | Advertisement | ||||||||||||||||||||||||||||||||||||
In this issue Comment News and Analysis Research Highlights Reviews Correspondence
|
| ||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Comment: Managing intellectual property to develop medicines for the world's poorest Sylvie Fonteilles-Drabek, David Reddy & Timothy N. C. Wells p223 | doi:10.1038/nrd.2017.24 It has been argued that patents impede the development and access of medicines for tropical diseases such as malaria. However, we believe that intellectual property can be a key tool to enable timely progression of drug development projects involving multiple partners and to ensure equitable access to successful products. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
NEWS AND ANALYSIS | Top | ||||||||||||||||||||||||||||||||||||
Fragment-based phenotypic screening is a hit Monya Baker p225 | doi:10.1038/nrd.2017.56 Libraries of functionalized small-molecule fragments that can be screened in whole cells could take phenotypic drug discovery to the next level, providing new opportunities against undertargeted proteins. | |||||||||||||||||||||||||||||||||||||
PRIME time at the EMA Asher Mullard p226 | doi:10.1038/nrd.2017.57 The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences. | |||||||||||||||||||||||||||||||||||||
NEWS IN BRIEF PARP inhibitors plough on Asher Mullard p229 | doi:10.1038/nrd.2017.61 | |||||||||||||||||||||||||||||||||||||
FDA approves Novartis's CDK4/6 inhibitor Asher Mullard p229 | doi:10.1038/nrd.2017.62 | |||||||||||||||||||||||||||||||||||||
TransCelerate makes progress Asher Mullard p229 | doi:10.1038/nrd.2017.63 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Patent watch: Patent insight into polymer-free drug-eluting stents Vadim Demidov, Daniel Currie & Justin Wen p230 | doi:10.1038/nrd.2017.32 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q2 2017 Eric Ho p231 | doi:10.1038/nrd.2017.47 | |||||||||||||||||||||||||||||||||||||
AN AUDIENCE WITH Jay Bradner p232 | doi:10.1038/nrd.2017.50 Jay Bradner, President of the Novartis Institutes for BioMedical Research, discusses increased interest in chemical biology and open science at Novartis. | |||||||||||||||||||||||||||||||||||||
FROM THE ANALYST'S COUCH The SCCHN drug market Jennifer Bamford & Rachel M. Webster p235 | doi:10.1038/nrd.2016.261 Two PD-1 directed checkpoint inhibitors have recently been approved for squamous cell carcinoma of the head and neck (SCCHN). Further checkpoint inhibitors, as well as other molecularly targeted agents and cytokine-based immunotherapies, are currently in the late-stage pipeline and are poised to change the treatment paradigm for SCCHN. | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
Marked for death: targeting epigenetic changes in cancer Sophia Xiao Pfister & Alan Ashworth p241 | doi:10.1038/nrd.2016.256 Human cancers commonly have mutations in epigenetic regulatory genes, and several small molecules that target epigenetic regulators are in clinical trials. Here, Pfister and Ashworth discuss the biological complexity of epigenetic regulation in cancer and provide an overview of inhibitors that target gain-of-function mutations, as well as synthetic lethal approaches to target loss-of-function mutations in epigenetic regulators. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity W. Joost Lesterhuis, Anthony Bosco, Michael J. Millward, Michael Small, Anna K. Nowak & Richard A. Lake p264 | doi:10.1038/nrd.2016.233 Immune checkpoint blockade is a powerful anticancer approach; however, it only works for some patients. Here, Lesterhuis and colleagues argue that response to immune checkpoint blockade is a critical state transition of a complex system. They discuss recent advances in mathematics and network biology that might facilitate the identification of dynamic biomarkers, which in turn might help distinguish responders from non-responders and determine new targets for combination therapy. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors Avi Ashkenazi, Wayne J. Fairbrother, Joel D. Leverson & Andrew J. Souers p273 | doi:10.1038/nrd.2016.253 The B cell lymphoma 2 (BCL-2) family of proteins has a key role in regulating apoptosis and is often dysregulated in cancer. This has led to the development of several inhibitors of pro-survival BCL-2 family proteins such as BCL-2, BCL-XL and MCL1, including the BCL-2 inhibitor venetoclax, which has recently gained regulatory approval. Here, Ashkenazi and colleagues discuss the latest progress in developing small-molecule inhibitors of pro-survival BCL-2 family proteins. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Applications of chemogenomic library screening in drug discovery Lyn H. Jones & Mark E. Bunnage p285 | doi:10.1038/nrd.2016.244 Chemogenomic screening is increasingly being applied to expedite the conversion of phenotypic screening projects into target-based drug discovery approaches. Here, Jones and Bunnage discuss the principles of the creation and use of chemogenomic libraries, highlighting key examples and their applications, including target identification, drug repositioning and predictive toxicology. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
CORRESPONDENCE | Top | ||||||||||||||||||||||||||||||||||||
Correspondence: To cleave or not to cleave: therapeutic gene editing with and without programmable nucleases Tod M. Woolf, Channabasavaiah B. Gurumurthy, Frederick Boyce & Eric B. Kmiec p296 | doi:10.1038/nrd.2017.42 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
|
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment